Recent Trends in the Diagnostic and Surgical Management of Benign Prostatic Hyperplasia in the U.S. from 2004 to 2017: Annual Changes in the Selection of Treatment Options and Medical Costs

Background: Transurethral resection of the prostate (TURP) is gold-standard treatment for benign prostatic hyperplasia (BPH). However, laser surgery techniques (e.g., photoselective vaporization (PVP), holmium laser, thulium enucleation (HoLEP or ThuLEP)), and minimally invasive options UroLift) are increasingly replacing TURP. This study seeks to report annual incidence, management trends, costs BPH procedures in U.S. Methods: Data analyses health insurance claims from 2004 2017, collected de-identified Optum Clinformatics Claims Database, were performed determine number patients selected. Results: A total 51,448 underwent 2017. There was a significant increase rate 770 6571 The mean patient age (±SD) increased 67.6 years old (±8.4) 73.4 More than 60% cystourethroscopy post-void residual urine check workup prior surgical management. TURP most-common, PVP second-most-common procedure. Medical increased, while detection cancer after gradually decreased 19.87% 5.78% Conclusions: Our demonstrates recent trend that replaces traditional technique with alternative methods. Due rising costs, future studies should assess whether these newer methods cost effective over long term.